• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Trendingnow

1

Philanthropy leader at Warren Buffett and Bill Gates’ Giving Pledge says children of billionaires are pushing them to give their wealth away faster

2

'Skills nobody can take': Meet a 20-year-old with a 4.5 GPA who skipped college for technical school to land an 'AI-proof' career

3

China suffers another setback in effort to de-dollarize global finance as anchor in the greenback's dominance quietly exits Beijing's payment scheme

1

Philanthropy leader at Warren Buffett and Bill Gates’ Giving Pledge says children of billionaires are pushing them to give their wealth away faster

2

'Skills nobody can take': Meet a 20-year-old with a 4.5 GPA who skipped college for technical school to land an 'AI-proof' career

3

China suffers another setback in effort to de-dollarize global finance as anchor in the greenback's dominance quietly exits Beijing's payment scheme
Opioid Crisis

Sacklers to Remain Billionaire Family If Purdue Settles Opioid Lawsuits

By
Tom Maloney
Tom Maloney
,
Jef Feeley
Jef Feeley
, and
Bloomberg
Bloomberg
Down Arrow Button Icon
By
Tom Maloney
Tom Maloney
,
Jef Feeley
Jef Feeley
, and
Bloomberg
Bloomberg
Down Arrow Button Icon
August 28, 2019, 12:20 PM ET
Google source logo
Add Fortune on Google for similar content.

The Sackler family — once known as global philanthropists backed by a fortune made from opioids and other drugs — may lose most of their wealth if they agree to an $11.5 billion settlement to resolve lawsuits against them and their Purdue Pharma LP. Even under this scenario they’ll remain far from the poorhouse.

When last valued by the Bloomberg Billionaires Index in March, the Sacklers were worth $13 billion.That included previous payouts from Purdue — court filings show the family made more than $4 billion from OxyContin sales from 2008 through 2015 — as well as their ownership of Mundipharma, a global network of independent associated companies they founded in 1952.

Their fortune will drop below $1.5 billion based on the terms of the proposal, which envisions the family paying at least $3 billion in cash. Purdue would file for bankruptcy, hand itself over to a trust controlled by the states, cities and counties that have sued. Mundipharma would also be sold. Its value may have declined since Bloomberg’s last estimate based on negative publicity. Overall, these actions would generate $11.5 billion to cover the fallout from the opioid epidemic, according to people with knowledge of the situation.

Bloomberg’s calculation is conservative as it excludes the family’s ownership of generic drugmaker Rhodes Pharmaceuticals LP, whose value couldn’t be determined. It also excludes dividends that Purdue may have paid prior to 2008, because the details weren’t public.

The clan’s fortune once made them celebrated global philanthropists, with gifts to New York’s Metropolitan Museum of Art and London’s Victoria and Albert Museum. The donations have drawn increasing criticism in recent years amid reports linking the Sacklers to the opioid crisis. The family is composed of the heirs of Purdue co-founders Mortimer and Raymond Sackler.

“The stain of this historic episode will be long-lasting,” said Gene Grabowski, a partner at communications firm kglobal, who specializes in crisis media relations. “The Sackler family and its decades of philanthropy will be overshadowed for at least a generation by its connection to the nation’s opioid epidemic.”

A representative for the Raymond side of the family didn’t immediately respond to questions about their wealth.

More must-read stories from Fortune:

—How the maker of the world’s bestselling drug keep prices sky-high
—Laundry pod exposures are rising for the first time since 2015
—This company will provide genetic counseling for a million person NIH study
—FCC: There is ‘overwelming support’ for short, 911-like suicide prevention hotline
—Listen to our audio briefing, Fortune 500 Daily
Follow Fortune on Flipboard to stay up-to-date on the latest news and analysis.

About the Authors
By Tom Maloney
See full bioRight Arrow Button Icon
By Jef Feeley
See full bioRight Arrow Button Icon
By Bloomberg
See full bioRight Arrow Button Icon

Latest in


Most Popular

Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

    Latest in


    Most Popular

    © 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
    FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.